Lancet:B群脑膜炎球菌外膜囊胞疫苗预防淋病的效果。

2017-07-11 qinqiyun MedSci原创

淋病是一主要的全球性公共健康问题,因耐药性而更加棘手。开发有效的疫苗尚未成功,但监测数据提示B群脑膜炎球菌外膜囊胞疫苗会影响淋病的发病率。研究人员对在新西兰15-30岁人群中脑膜炎球菌外膜囊胞B疫苗(MeNZB)抗淋病的效果进行评估。

淋病是一主要的全球性公共健康问题,因耐药性而更加棘手。开发有效的疫苗尚未成功,但监测数据提示B群脑膜炎球菌外膜囊胞疫苗会影响淋病的发病率。研究人员对在新西兰15-30岁人群中脑膜炎球菌外膜囊胞B疫苗(MeNZB)抗淋病的效果进行评估。

研究人员对性健康诊所的15-30岁(1984年1月1日-1998年12月31日之间出生)患者进行一个回顾性病例对照研究,这些患者适合接种MeNZB,并诊断有淋病或衣原体感染或都有。人口数据、性健康诊所数据和国家免疫登记数据通过患者独特个人标识相联系。病例是由实验室隔离确诊或仅检测临床样本中的淋球菌,对照组是只有衣原体测试阳性的个体。研究人员通过多变量逻辑回归估算接种疫苗和未接种疫苗的人群中发病结果的优势比(ORs)。

在全国24家诊断中的11家提供记录。共有14730例病例和对照:1241例淋病、12487例衣原体感染和1002例共感染。与对照相比接种疫苗的个体发病率明显下降((511 [41%]比6424 [51%]; OR 0.69 [95% CI 0.61–0.79]; p<0.0001)。根据种族、贫困、地理区域和性别调整后MeNZB预防淋病的疫苗效果是31%。

接种MeNZB可以降低淋病的发病率,第一次有疫苗可以在一定程度上预防淋病。这些结果表明未来疫苗开发不仅是为了淋球菌疫苗还为了脑膜炎球菌疫苗。

原始出处:

Helen Petousis-Harris, Janine Paynter,et al.Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study.The Lancet.10 July 2017.http://dx.doi.org/10.1016/S0140-6736(17)31449-6

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1829074, encodeId=d85618290e497, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Nov 28 20:23:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953634, encodeId=311a1953634cb, content=<a href='/topic/show?id=ebace05389b' target=_blank style='color:#2F92EE;'>#疫苗预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70538, encryptionId=ebace05389b, topicName=疫苗预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c805395, createdName=ycmayy, createdTime=Mon Aug 28 10:23:00 CST 2017, time=2017-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221937, encodeId=285122193e46, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu Jul 13 19:01:02 CST 2017, time=2017-07-13, status=1, ipAttribution=)]
    2017-11-28 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1829074, encodeId=d85618290e497, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Nov 28 20:23:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953634, encodeId=311a1953634cb, content=<a href='/topic/show?id=ebace05389b' target=_blank style='color:#2F92EE;'>#疫苗预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70538, encryptionId=ebace05389b, topicName=疫苗预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c805395, createdName=ycmayy, createdTime=Mon Aug 28 10:23:00 CST 2017, time=2017-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221937, encodeId=285122193e46, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu Jul 13 19:01:02 CST 2017, time=2017-07-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1829074, encodeId=d85618290e497, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Nov 28 20:23:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953634, encodeId=311a1953634cb, content=<a href='/topic/show?id=ebace05389b' target=_blank style='color:#2F92EE;'>#疫苗预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70538, encryptionId=ebace05389b, topicName=疫苗预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c805395, createdName=ycmayy, createdTime=Mon Aug 28 10:23:00 CST 2017, time=2017-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221937, encodeId=285122193e46, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu Jul 13 19:01:02 CST 2017, time=2017-07-13, status=1, ipAttribution=)]
    2017-07-13 1dd8c52fm63(暂无匿称)

    继续关注

    0